By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
All News
Article
Article
At EULAR 2022, I look forward to key topics and presentations in psoriatic arthritis (PsA). Here's a preview of nine studies I'm particularly interested in at this meeting.
Article
Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.
Article
Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.
Eric Dein
Tweet
#EULAR2022 LB0001
Bimekizumab (IL-17F and IL-17A) in bionaive PsA
BE OPTIMAL phase 3 trial, 24 weeks
⭐️Met Primary endpt - ACR50
⭐️Met other ACR and PASI endpts
⭐️Safety: higher fungal infections
@RheumNow https://t.co/x8u6B93FNl
Aurelie Najm
Tweet
BE OPTIMAL Phase 3 RCT
Bimekizumab dual IL17A & F inhibitor in bionaive PsA
⭐️ACR50 wk 16 43.9% vs 10% PBO
⭐️PASI 90 wk 16 61% vs. 3% PBO
⭐️separation from wk 4
Safety: fungal injections BKZ > ADA
@RheumNow
LB0001 #EULAR2022 https://t.co/7ZwV1XDSNb
Aurelie Najm
Tweet
CorEvitas PsA Registry (1000+ pts)
Analysis of biologics prescription according to disease domains
No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL
Overall first line TNFi 40% > IL-17i 14%
POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
Richard Conway
Tweet
Castrejon et al. BIOBADASER registry study. Cancer risk with various bDMARDs. Overall I don't think there is a difference here. Lowest in IL17i and highest in abatacept but older and comorbidity confounders @RheumNow #EULAR2022 #POS1439 https://t.co/gfv78ouOTJ
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients
Fast onset, met ACR50 primary endpoint
AE included site reaction and candida infection
@RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Richard Conway
Tweet
Merola et al. BE COMPLETE trial of bimekizumab (dual 17A/17Fi) in TNF-IR PsA. Week 16 ACR50: 43.4% BKZ vs 6.8% PBO. Rapid response with separation from week 4. @RheumNow #EULAR2022 OP0255 https://t.co/ZaxAeePP6L https://t.co/D5mDdkno3c
Richard Conway
Tweet
Behrens et al. Izokibep (small molecular size IL17Ai, suggested to abrogate issues with tissue distribution of monoclonal abs) in PsA. ACR50 52% in 80mg, 48% in 40mg, 13% in PBO. @RheumNow #EULAR2022 https://t.co/FUS50ax79C https://t.co/e1n1RbNw1b
Aurelie Najm
Tweet
BE COMPLETE RCT
Bimekizumab vs. PBO in TNFiIR PsA pts
meets its primary criteria at 16wks w/
-ACR50 43%
-PASI 90 69%
and MDA achieved in 40+% pts
No new safety signal.
@RheumNow #EULAR2022 OP0255 https://t.co/QazYlzDqIc
Dr. Antoni Chan
Tweet
Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts.
@RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC
Eric Dein
Tweet
#EULAR2022 ASAS/EULAR AxSpA Recs
⭐️Last: 2016
▶️All: education, exercise, 🚭
▶️❌csDMARD for axial disease
▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1
▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17
▶️Sustained remission: tapering of bDMARD "can be considered"
@RheumNow https://t.co/3yYU0Vb37r
Janet Pope
Tweet
Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t
Richard Conway
Tweet
Bimekizumab (dual 17A/17F inhibitor) RCT in AS. ASAS40 45% vs 23% at week 16. All secondary clinical and imaging endpoints also + @RheumNow #EULAR2022 OP0019 https://t.co/RiZ7Divap3 https://t.co/ushogL5TaX
Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%).
#EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS
